BerGenBio ASA Presents at Global Investment Conference

BerGenBio ASA (BRRGF) has released an update.

BerGenBio ASA, a Norway-based biopharmaceutical company, is set to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, where CEO Martin Olin will discuss the latest updates on their clinical study for a novel lung cancer treatment. The company is advancing its leading drug candidate, bemcentinib, targeting AXL kinase inhibitors for the treatment of aggressive diseases, including specific lung cancers and severe respiratory infections. Interested parties can access the conference presentation on the BerGenBio website’s investor section.

For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.